Cytokinetics (MIL:1CYTK) Cyclically Adjusted Revenue per Share: €0.86 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1CYTK Cytokinetics Inc MIL:1CYTK
31 GF Score
Price €66.14
GF Value €171.17
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cytokinetics Cyclically Adjusted Revenue per Share?

Cytokinetics MIL:1CYTK 31 Cyclically Adjusted Revenue per Share is €0.86 as of Jun. 2026. GuruFocus rates MIL:1CYTK with a GF Score™ of 31/100 and a GF Value™ of €171.17 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cytokinetics's adjusted revenue per share for the three months ended in Jun. 2026 was €0.188. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.86 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Cytokinetics's average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -7.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cytokinetics was 10.30% per year. The lowest was -39.20% per year. And the median was -7.00% per year.

As of today (2026-08-15), Cytokinetics's current stock price is €66.14. Cytokinetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.86. Cytokinetics's Cyclically Adjusted PS Ratio of today is 76.91.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cytokinetics was 89.16. The lowest was 3.22. And the median was 27.59.


Cytokinetics  (MIL:1CYTK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cytokinetics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=66.14/0.86
=76.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cytokinetics was 89.16. The lowest was 3.22. And the median was 27.59.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cytokinetics Cyclically Adjusted Revenue per Share Related Terms


Cytokinetics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cytokinetics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics Cyclically Adjusted Revenue per Share Chart

Cytokinetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.78

Cytokinetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.83 0.78 0.81 0.86

MIL:1CYTK vs SMMT, TECH, BMRN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted PS Ratio falls into.


MIL:1CYTK
31GF Score
Cytokinetics Inc MIL:1CYTK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytokinetics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cytokinetics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.188/333.9520*333.9520
=0.188

Current CPI (Jun. 2026) = 333.9520.

Cytokinetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.217 241.428 1.683
201612 0.722 241.432 0.999
201703 0.093 243.801 0.127
201706 0.056 244.955 0.076
201709 0.097 246.819 0.131
201712 0.000 246.524 0.000
201803 0.079 249.554 0.106
201806 0.098 251.989 0.130
201809 0.167 252.439 0.221
201812 0.151 251.233 0.201
201903 0.137 254.202 0.180
201906 0.110 256.143 0.143
201909 0.094 256.759 0.122
201912 0.079 256.974 0.103
202003 0.058 258.115 0.075
202006 0.054 257.797 0.070
202009 0.518 260.280 0.665
202012 0.078 260.474 0.100
202103 0.077 264.877 0.097
202106 0.033 271.696 0.041
202109 0.058 274.310 0.071
202112 0.585 278.802 0.701
202203 0.012 287.504 0.014
202206 0.982 296.311 1.107
202209 0.027 296.808 0.030
202212 0.020 296.797 0.023
202303 0.045 301.836 0.050
202306 0.008 305.109 0.009
202309 0.004 307.789 0.004
202312 0.015 306.746 0.016
202403 0.008 312.332 0.009
202406 0.002 314.175 0.002
202409 0.004 315.301 0.004
202412 0.137 315.605 0.145
202503 0.012 319.799 0.013
202506 0.485 322.561 0.502
202509 0.014 324.800 0.014
202512 0.124 324.054 0.128
202603 0.136 330.213 0.138
202606 0.188 333.952 0.188

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.86 mean?
Cytokinetics (MIL:1CYTK) has a Cyclically Adjusted Revenue per Share of €0.86 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cytokinetics and its competitors.
Is Cytokinetics' Cyclically Adjusted Revenue per Share too high?
Cytokinetics' current Cyclically Adjusted Revenue per Share is €0.86. Overall, Cytokinetics has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cytokinetics' Cyclically Adjusted Revenue per Share compare to SMMT and TECH?
Cytokinetics' Cyclically Adjusted Revenue per Share of €0.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cytokinetics and its competitors. Cytokinetics's current Cyclically Adjusted Revenue per Share is €0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytokinetics stock overvalued right now?
Based on GuruFocus' analysis, Cytokinetics (MIL:1CYTK) is currently considered Possible Value Trap. The stock's GF Value™ is €171.17, compared to a current price of €66.14 — trading 61.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.86. Cytokinetics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cytokinetics (MIL:1CYTK), the current Cyclically Adjusted Revenue per Share is €0.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytokinetics (MIL:1CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €66.14 is trading 61.4% below its estimated GF Value™ of €171.17. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for MIL:1CYTK:

  • Cyclically Adjusted Revenue per Share: €0.86
  • GF Value™: €171.17 vs. price of €66.14 (61.4% below fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the MIL:1CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cytokinetics Business Description

Other Exchanges CYTK:USAKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
31GF Score

Get the complete analysis for MIL:1CYTK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.14
Price
€171.17
GF Value